Clincosm LogoSign in Get a demo

CONTACT-03: A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment

Sponsor
Hoffmann-La Roche (Industry)
Overall Status
Active, not recruiting
CT.gov ID
NCT04338269
Collaborator
Exelixis (Industry), Chugai (Other)
523
Enrollment
152
Locations
2
Arms
52.5
Anticipated Duration (Months)
3.4
Patients Per Site
0.1
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is a Phase III, multicenter, randomized, open-label study designed to evaluate the efficacy and safety of atezolizumab given in combination with cabozantinib versus cabozantinib alone in participants with inoperable, locally advanced, or metastatic renal cell carcinoma (RCC) who experienced radiographic tumor progression during or after Immune Checkpoint Inhibitor (ICI) treatment in the metastatic setting.

Condition or Disease Intervention/Treatment Phase
Phase 3

Study Design

Study Type:
Interventional
Actual Enrollment :
523 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Phase III, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Atezolizumab Given in Combination With Cabozantinib Versus Cabozantinib Alone in Patients With Inoperable, Locally Advanced, or Metastatic Renal Cell Carcinoma Who Experienced Radiographic Tumor Progression During or After Immune Checkpoint Inhibitor Treatment
Actual Study Start Date :
Jul 28, 2020
Anticipated Primary Completion Date :
Sep 15, 2022
Anticipated Study Completion Date :
Dec 11, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Atezo+Cabo

Participants will receive atezolizumab every 3 weeks on Day 1 of each 21-day cycle (1 cycle=21 days) plus oral tablets of cabozantinib every day.

Drug: Atezolizumab
Atezolizumab 1200 mg will be administered at a fixed dose on Day 1 of each 21-day cycle by IV infusion every 3 weeks.
Other Names:
  • Tecentriq

    • Drug: Cabozantinib
    Cabozantinib 60 mg (three 20-mg tablets) administered orally once daily.
    Other Names:
  • Cabometyx

    		•
    Active Comparator: Cabozantinib

    Participants will receive cabozantinib every day.

    Drug: Cabozantinib
    Cabozantinib 60 mg (three 20-mg tablets) administered orally once daily.
    Other Names:
  • Cabometyx

    		•

    Outcome Measures

    Primary Outcome Measures

    1. Progression-Free Survival (PFS), as assessed by Independent Review Facility (IRF) [Randomization up to approximately 27 months]

      Progression-free survival (PFS), defined as the time from randomization to the first occurrence of disease progression according to RECIST v1.1, as assessed by Independent Review Facility (IRF-PFS) or death from any cause, whichever occurs first.

    2. Overall survival (OS) [Randomization up to approximately 52 months]

      Overall survival (OS), defined as the time from randomization to death from any cause.

    Secondary Outcome Measures

    1. PFS Assessed by the Investigators (INV-PFS) [Randomization up to approximately 27 months]

      PFS assessed by the investigators (INV-PFS), defined as the time from randomization to the first occurrence of disease progression according to RECIST v1.1 or death from any cause (whichever occurs first).

    2. Investigator Assessed Objective Response Rate (INV-ORR) [Randomization up to approximately 27 months]

      INV-ORR, defined as the proportion of patients with a complete response (CR) or partial response (PR) on two consecutive occasions at least 4 weeks apart according to RECIST v1.1.

    3. IRF Assessed Objective Response Rate (IRF-ORR) [Randomization up to approximately 27 months]

      IRF-ORR, defined as the proportion of patients with a complete response (CR) or partial response (PR) on two consecutive occasions at least 4 weeks apart according to RECIST v1.1.

    4. Investigator Assessed Duration of Objective Response (INV-DOR) [Randomization up to approximately 27 months]

      INV-DOR, defined as the time from the first occurrence of a documented objective response to disease progression or death from any cause (whichever occurs first) according to RECIST v1.1.

    5. IRF Assessed DOR (IRF-DOR) [Randomization up to approximately 27 months]

      IRF-DOR, defined as the time from the first occurrence of a documented objective response to disease progression or death from any cause (whichever occurs first) according to RECIST v1.1.

    6. Percentage of Participants With Adverse Events [Randomization up to approximately 27 months]

    7. Atezolizumab Concentrations [At pre-defined intervals from first administration of study drug up to approximately 27 months]

    8. Cabozantinib Concentrations [At pre-defined intervals from first administration of study drug up to approximately 27 months]

    9. Prevalence of Anti-Drug Antibodies (ADAs) to Atezolizumab [Baseline]

    10. Incidence of ADAs to Atezolizumab During the Study [At pre-defined intervals from first administration of study drug up to approximately 27 months]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • Histologically confirmed locally advanced or metastatic clear cell or non-clear cell (papillary, chromophobe, and unclassified only) RCC. RCC with sarcomatoid features is allowed. Patients with the chromophobe subtype of non-clear cell RCC must have sarcomatoid differentiation.

    • Radiographic disease progression to prior ICI therapy for RCC. Patients who experienced radiographic tumor progression during or within 6 months after the last dose of adjuvant ICI are also eligible. ICI is defined by anti-PD-L1 or anti-PD1 antibody including atezolizumab, avelumab, pembrolizumab, durvalumab, or nivolumab. Only patients for whom the immediate preceding line of therapy was an ICI are allowed.

    • Measurable disease per RECIST v1.1

    • Evaluable IMDC risk score

    • Archival tumor specimen, and pretreatment tumor tissue from fresh biopsy at screening, if clinically feasible. Both archival and fresh samples are preferred.

    • KPS score of >=70

    • Recovery to baseline or Grade </= 1 NCI CTCAE v5.0 from toxicities related to any prior treatments, unless adverse events are clinically nonsignificant and/or stable in the opinion of the investigator. Grade 2 alopecia is allowed for study participation

    • Adequate hematologic and end-organ function

    • Negative HIV test at screening

    • Negative hepatitis B testing at screening

    • Negative hepatitis C virus (HCV) antibody test at screening, or positive HCV antibody test followed by a negative HCV RNA test at screening

    • For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception and agreement to refrain from donating eggs

    • For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm

    Exclusion Criteria:

    • Treatment with anti-cancer therapy within 14 days prior to initiation of study treatment

    • Patients received cabozantinib at any time prior to screening

    • Patients who received more than one ICI treatment in the locally advanced or metastatic setting

    • Patients who received more than two prior lines of therapy in the locally advanced or metastatic setting

    • Patients who have received a mammalian target of rapamycin (mTOR) inhibitor in any setting

    • Symptomatic, untreated, or actively progressing CNS metastases

    • History of leptomeningeal disease

    • Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures

    • Uncontrolled or symptomatic hypercalcemia or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy or denosumab

    • History of malignancy other than renal carcinoma within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death

    • Radiotherapy for RCC within 14 days prior to Day 1 of Cycle 1

    • Active tuberculosis

    • Major surgical procedure, other than for diagnosis, within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study

    • Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment or within 5 months after final dose of atezolizumab and 4 months after final dose of cabozantinib

    • Severe infection within 4 weeks prior to initiation of study treatment, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia, or any active infection that, in the opinion of the investigator, could impact patient safety

    • Pharmacologically uncompensated, symptomatic hypothyroidism

    • Uncontrolled hypertension defined as sustained blood pressure >150 mm Hg systolic or > 90 mm Hg diastolic despite optimal antihypertensive treatment

    • Significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, unstable arrhythmia, or unstable angina) within 3 months prior to initiation of study treatment

    • Significant vascular disease (e.g., aortic aneurysm or arterial dissection requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to Day 1 of Cycle 1

    • History of congenital QT syndrome

    • History or presence of an abnormal ECG that is clinically significant in the investigator's opinion

    • Concomitant anticoagulation with coumarin agents (e.g., warfarin), direct thrombin inhibitor dabigatran, direct factor Xa inhibitor betrixaban, or platelet inhibitors (e.g. clopidogrel)

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of Arizona Tucson Arizona United States 85724-5030
    2 City of Hope Comprehensive Cancer Center Duarte California United States 91010
    3 UC San Diego Health System La Jolla California United States 92093
    4 UCLA Los Angeles California United States 90095
    5 University of Colorado Aurora Colorado United States 80045
    6 Rocky Mountain Cancer Center - Denver Littleton Colorado United States 80120
    7 Sibley Memorial Hospital Washington District of Columbia United States 20016
    8 Woodlands Medical Specialists, P.A. Pensacola Florida United States 32503
    9 Moffitt Cancer Center Tampa Florida United States 33612
    10 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Skip Viragh Outpatient Cancer Building Baltimore Maryland United States 21287
    11 MGH Boston Massachusetts United States 02114
    12 Beth Israel Deaconess Med Ctr Boston Massachusetts United States 02215
    13 Dana-Farber Cancer Institute Boston Massachusetts United States 02215
    14 Minnesota Oncology Hematology Saint Paul Minnesota United States 55102
    15 Comprehensive Cancer Centers of Nevada (CCCN) - Central Valley Las Vegas Nevada United States 89169
    16 Memorial Sloan Kettering - Monmouth Middletown New Jersey United States 07748
    17 Memorial Sloan Kettering Bergen Montvale New Jersey United States 07645
    18 New York Oncology Hematology,P.C.-Albany Albany New York United States 12208
    19 Montefiore Medical Center Bronx New York United States 10461
    20 Memorial Sloan Kettering Cancer Center - Commack Commack New York United States 11725
    21 MSKCC @ West Harrison Harrison New York United States 10604
    22 Mount Sinai Medical Center New York New York United States 10029
    23 Memorial Sloan Kettering Cancer Center New York New York United States 10065
    24 SUNY Upstate Medical University Syracuse New York United States 13210
    25 Duke University Medical Center Durham North Carolina United States 27710
    26 Cleveland Clinic Cleveland Ohio United States 44106
    27 Fox Chase Cancer Center Philadelphia Pennsylvania United States 19111
    28 Texas Onc-Central Austin CA Ct Austin Texas United States 78731
    29 University Of Utah Salt Lake City Utah United States 84108
    30 Virginia Cancer Specialists - Gainsville Gainesville Virginia United States 20155
    31 Fundación CENIT para la Investigación en Neurociencias Buenos Aires Argentina C1125ABD
    32 Inst. Alexander Fleming; Oncologia Buenos Aires Argentina C1426ANZ
    33 Hospital Britanico Ciudad Autonoma Bs As Argentina C1280AEB
    34 Centro Medico Austral OMI Ciudad Autonoma Buenos Aires Argentina C1019ABS
    35 Macquarie University Hospital Macquarie Park New South Wales Australia 2109
    36 Orange Hospital Orange New South Wales Australia 2800
    37 Icon Cancer Foundation South Brisbane Queensland Australia 4101
    38 Bendigo Cancer Centre Bendigo Victoria Australia 3550
    39 Cancer Care Manitoba Winnipeg Manitoba Canada R3E 0V9
    40 St. Joseph's Healthcare Hamilton Hamilton Ontario Canada L8N 4A6
    41 Princess Margaret Cancer Center Toronto Ontario Canada M5G 1Z5
    42 Herlev Hospital; Afdeling for Kræftbehandling Herlev Denmark 2730
    43 CHU Besançon - Hôpital Jean Minjoz Besançon Cedex France 25030
    44 CHU de Bordeaux - Groupe Hospitalier Saint-André - Hopital Saint-Andre Bordeaux France 33075
    45 Centre Francois Baclesse; Oncologie Caen France 14076
    46 Centre Jean Perrin; Oncologie Clermont Ferrand France 63011
    47 Centre Oscar Lambret; Chir Cancerologie General Lille France 59000
    48 Centre Leon Berard; Departement Oncologie Medicale Lyon France 69373
    49 Centre Antoine Lacassagne Nice France 06189
    50 Institut de cancerologie du Gard Nimes France 30029
    51 Hopital Europeen Georges Pompidou; Service D'Oncologie Medicale Paris France 75908
    52 ICANS Strasbourg France 67200
    53 Institut Gustave Roussy; Oncologie Medicale Villejuif France 94800
    54 Zeisigwaldkliniken Bethanien Chemnitz Germany 09130
    55 Klinikum der Johann Wolfgang Goethe-Universitaet; Urologie und Kinderurologie Frankfurt Germany 60590
    56 Universitaetsklinikum Freiburg; Urology Freiburg Germany 79106
    57 Krankenhaus Martha-Maria Halle-Dölau, Klinik für Urologie Halle (Saale) Germany 06120
    58 Uniklinik-Eppendorf; Klinik U Poliklinik F Urologie Hamburg Germany 20246
    59 Med. Hochschule Hannover, Hämatologie, Hämostaseologie, Onkologie u. Stammzelltransplantation Hannover Germany 30625
    60 Universitaetsklinikum Muenster; Urology Muenster Germany 48149
    61 Klinikum rechts der Isar der TU München; Urologische Klinik und Poliklinik München Germany 81675
    62 Universitätsklinikum Tübingen; Klinik für Urologie Tübingen Germany 72076
    63 Universitätsklinikum Ulm; Klinik für Urologie Ulm Germany 89081
    64 Attikon University General Hospital Ahens Greece 124 64
    65 Alexandras General Hospital of Athens; Oncology Department Athens Greece 115 28
    66 Athens Medical Center; Dept. of Oncology Athens Greece 151 25
    67 University Hospital of Larissa;Department of Medical Oncology Larissa Greece 411 10
    68 Papageorgiou General Hospital; Medical Oncology Thessaloniki Greece 564 29
    69 Diavalkaniko Hospital Thessaloniki Greece 570 01
    70 Istituto Tumori Napoli;Unità Operativa Oncologia Medica Uro-Ginecologica Napoli Campania Italy 80131
    71 Azienda Ospedaliero-Universitaria S.Orsola-Malpighi; Unità Operativa Oncologia Medica Bologna Emilia-Romagna Italy 40138
    72 IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica Meldola Emilia-Romagna Italy 47014
    73 Irccs Centro Di Riferimento Oncologico (CRO); SOC Oncologia Medica A Aviano (PN) Friuli-Venezia Giulia Italy 33081
    74 Policlinico Universitario "Agostino Gemelli"; U.O.C. Oncologia Medica Roma Lazio Italy 00168
    75 ASST DEGLI SPEDALI CIVILI DI BRESCIA; Oncologia Medica Brescia Lombardia Italy 25123
    76 Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2 Milano Lombardia Italy 20133
    77 Fondazione Salvatore Maugeri; Divisione Di Oncologia Medica Pavia Lombardia Italy 27100
    78 Istituto Clinico Humanitas;U.O. Oncologia Medica Ed Ematologia Rozzano Lombardia Italy 20089
    79 Ospedale Di Macerata; Oncologia Macerata Marche Italy 62100
    80 Fondazione del Piemonte per l'Oncologia (IRCCS); Day Hospital Oncologico Multidisciplinare Candiolo (TO) Piemonte Italy 10060
    81 A.O. Universitaria Ospedale Consorziale Policlinico Di Bari; U.O. Oncologia Medica Universitaria Bari Puglia Italy 70124
    82 Azienda Ospedaliera S. Maria - Terni; Oncologia Terni Umbria Italy 05100
    83 A.O.U di Verona Policlinico G.B. Rossi; Centro Ricerche Cliniche Verona Veneto Italy 37134
    84 Kyushu University Hospital Fukuoka Japan 812-8582
    85 Hokkaido University Hospital Hokkaido Japan 060-8648
    86 University of Tsukuba Hospital Ibaraki Japan 305-8576
    87 Yokohama City University Hospital Kanagawa Japan 236-0004
    88 Okayama University Hospital Okayama Japan 700-8558
    89 Osaka Metropolitan University Hospital Osaka Japan 545-8586
    90 Kindai University Hospital Osaka Japan 589-8511
    91 Tokushima University Hospital Tokushima Japan 770-8503
    92 Keio University Hospital Tokyo Japan 160-8582
    93 Tokyo Women's Medical University Hospital Tokyo Japan 162-8666
    94 Chungnam National University Hospital Daejeon Korea, Republic of 35015
    95 National Cancer Center Goyang-si Korea, Republic of 10408
    96 CHA Bundang Medical Center Gyeonggi-do Korea, Republic of 13496
    97 Pusan National University Yangsan Hospital Gyeongsangnam-do Korea, Republic of 50612
    98 Chonnam National University Hwasun Hospital Jeollanam-do Korea, Republic of 58128
    99 Seoul National University Bundang Hospital Seongnam-si Korea, Republic of 13605
    100 Seoul National University Hospital Seoul Korea, Republic of 03080
    101 Kangbuk Samsung Medical Center Seoul Korea, Republic of 03181
    102 Severance Hospital Seoul Korea, Republic of 03722
    103 Asan Medical Center Seoul Korea, Republic of 05505
    104 Samsung Medical Center Seoul Korea, Republic of 06351
    105 Szpital Specjalistyczny Podkarpacki Ośrodek Onkologiczny Brzozów Poland 36-200
    106 Centrum Onkologii im. Prof. Franciszka Łukaszczyka; Ambulatorium Chemioterapii Bydgoszcz Poland 85-796
    107 SP ZOZ Wojewódzki Szpital Specjalistyczny nr 4; Oddzial Onkologii Klinicznej Bytom Poland 41-902
    108 Centrum Terapii Wspolczesnej J.M.Jasnorzewska Spolka Komandytowo-Akcyjna Lodz Poland 90-242
    109 Europejskie Centrum Zdrowia Otwock Szpital im. Fryderyka Chopina, Klinika Onkologii Otwock Poland 05-400
    110 Szpital Kliniczny Przemienienia Pańskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego Poznan Poland 60-570
    111 Szpital Grochowski im. dr med. Rafała Masztaka Sp. z o.o. Warszawa Poland 04-073
    112 Wojskowy Instytut Medyczny; Klinika Onkologii Warszawa Poland 04-141
    113 Dolnośląskie Centrum Onkologii, Pulmonologii i Hematologii Wrocław Poland 53-413
    114 Regional Clinical Oncology Hospital Yaroslavl Jaroslavl Russian Federation 150054
    115 Branch of the company "Hadassah Medical LTD" Innovatsionnogo Tsentra Skolkovo Moskovskaja Oblast Russian Federation 121205
    116 MEDSI Clinical Hospital on Pyatnitsky Highway; Department of antitumor drug therapy Moscow Moskovskaja Oblast Russian Federation 143422
    117 SBIH "Moscow Clinical Scientific and Practical Center named after A.S. Loginov of DHM" Moskva Moskovskaja Oblast Russian Federation 111123
    118 National Medical Research Center for Surgery named after A.V. Vishnevsky Moskva Moskovskaja Oblast Russian Federation 117997
    119 AV Medical Ltd. Sait-Petersburg Sankt Petersburg Sankt Petersburg Russian Federation 196006
    120 Private Healthcare Institution Clinical Hospital RZhD Medicine St. Petersburg Sankt Petersburg Russian Federation 195271
    121 St-Petersburg Regional Oncology Dispensary; Oncology Kuzmolovo Russian Federation 188663
    122 FSBSI "Russian Oncological Scientific Center n.a. N.N. Blokhin" Moscow Russian Federation 115478
    123 Medical Center Avicenna; Urology Novosibirsk Russian Federation 630099
    124 Hospital Univ. Central de Asturias; Servicio de Oncologia Oviedo Asturias Spain 33011
    125 Corporacio Sanitaria Parc Tauli; Servicio de Oncologia Sabadell Barcelona Spain 8208
    126 Hospital Universitario Marques de Valdecilla; Servicio de Oncologia Santander Cantabria Spain 39008
    127 Hospital Universitario Reina Sofia; Servicio de Oncologia Córdoba Cordoba Spain 14004
    128 Hospital Universitario Son Espases; Servicio de Oncologia Palma De Mallorca Islas Baleares Spain 07014
    129 Hospital Universitario Puerta de Hierro; Servicio de Oncologia Majadahonda Madrid Spain 28222
    130 Hospital Alvaro Cunqueiro; Servicio de Oncologia Vigo Pontevedra Spain 36213
    131 Vall d´Hebron Institute of Oncology (VHIO), Barcelona Barcelona Spain 08035
    132 Hospital de la Santa Creu i Sant Pau; Servicio de Oncologia Barcelona Spain 08041
    133 Hospital Universitario de Burgos; Oncología Burgos Spain 09006
    134 Hospital San Pedro De Alcantara; Servicio de Oncologia Caceres Spain 10003
    135 Hospital Lucus Augusti; Servicio de Oncologia Lugo Spain 27003
    136 Hospital General Universitario Gregorio Marañon; Servicio de Oncologia Madrid Spain 28007
    137 Hospital Ramon y Cajal; Servicio de Oncologia Madrid Spain 28034
    138 Hospital Clinico San Carlos; Servicio de Oncologia Madrid Spain 28040
    139 Hospital Universitario 12 de Octubre; Servicio de Oncologia Madrid Spain 28041
    140 Hospital Universitario La Paz; Servicio de Oncologia Madrid Spain 28046
    141 Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia Malaga Spain 29010
    142 Hospital Universitario Virgen de Arrixaca; Servicio de Oncologia Murcia Spain 30120
    143 Hospital de Navarra; Servicio de Oncologia Navarra Spain 31008
    144 Hospital Universitario Virgen del Rocio; Servicio de Oncologia Sevilla Spain 41013
    145 Hospital Univ. Nuestra Señora de Valme; Servicio de Oncologia Sevilla Spain 41014
    146 Hospital Universitario la Fe; Servicio de Oncologia Valencia Spain 46026
    147 Royal Blackburn Hospital Blackburn United Kingdom BB2 3HH
    148 Leicester Royal Infirmary; Dept. of Medical Oncology Leicester United Kingdom LE1 5WW
    149 Barts & London School of Med; Medical Oncology London United Kingdom EC1A 7BE
    150 Royal Marsden Hospital; Dept of Med-Onc London United Kingdom SW3 6JJ
    151 Christie Hospital Nhs Trust; Medical Oncology Manchester United Kingdom M2O 4BX
    152 Royal Marsden Hospital (Sutton) Sutton United Kingdom SM2 5PT

    Sponsors and Collaborators

    • Hoffmann-La Roche
    • Exelixis
    • Chugai

    Investigators

    • Study Director: Clinical Trials, Hoffmann-La Roche

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Hoffmann-La Roche
    ClinicalTrials.gov Identifier:
    NCT04338269
    Other Study ID Numbers:
    • WO41994
    First Posted:
    Apr 8, 2020
    Last Update Posted:
    Jun 16, 2022
    Last Verified:
    Jun 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Carcinoma
    Carcinoma, Renal Cell
    Atezolizumab

    Study Results

    No Results Posted as of Jun 16, 2022